11:13 AM EDT, 08/27/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday that China's National Medical Products Administration has approved the company's cell therapy product ciltacabtagene autoleucel to treat adult patients with relapsed or refractory multiple myeloma, who received at least three previous lines of therapy.

Ciltacabtagene autoleucel, or cilta-cel, is a gene-modified therapy targeting B-cell maturation antigen that offers a novel treatment for patients in China who have not seen improvement from traditional therapies.

The approval was based on the firm's CARTIFAN-1 multi-center confirmatory phase II clinical study that evaluated the efficacy and safety of cilta-cel, Legend Biotech ( LEGN ) said.

Price: 56.39, Change: -0.25, Percent Change: -0.43